Corcept Therapeutics Inc.
CORT Real Time Price USDRecent trades of CORT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CORT's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
CORT Revenue by Segment or Geography
New patents grants
-
Patent Title: Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators Apr. 01, 2025
-
Patent Title: Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Feb. 18, 2025
-
Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Feb. 18, 2025
-
Patent Title: Quaternary indazole glucocorticoid receptor antagonists Dec. 31, 2024
-
Patent Title: Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors Dec. 24, 2024
-
Patent Title: Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Nov. 26, 2024
-
Patent Title: Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators Nov. 19, 2024
-
Patent Title: Octahydro fused azadecalin glucocorticoid receptor modulators Nov. 12, 2024
-
Patent Title: Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators Nov. 12, 2024
-
Patent Title: Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers Oct. 08, 2024
-
Patent Title: Treatment of hypercoagulopathy in cushing's syndrome by administration of glucocorticoid receptor modulators Oct. 01, 2024
-
Patent Title: Piperazine indazole glucocorticoid receptor antagonists Sep. 24, 2024
-
Patent Title: Bicyclic indazole glucocorticoid receptor antagonists Sep. 24, 2024
-
Patent Title: Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors Sep. 24, 2024
-
Patent Title: Pyrimidine cyclohexenyl glucocorticoid receptor modulators Jun. 25, 2024
-
Patent Title: Methods for shrinking pituitary tumors Jun. 11, 2024
-
Patent Title: Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors Apr. 30, 2024
-
Patent Title: Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 Apr. 02, 2024
-
Patent Title: Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound Mar. 12, 2024
-
Patent Title: Methods of treating antipsychotic-induced weight gain with miricorilant Feb. 20, 2024
-
Patent Title: Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency Feb. 06, 2024
-
Patent Title: Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators Nov. 28, 2023
-
Patent Title: Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators Oct. 24, 2023
-
Patent Title: Quaternary indazole glucocorticoid receptor antagonists Oct. 17, 2023
-
Patent Title: Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators Sep. 19, 2023
-
Patent Title: Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of cushing's syndrome patients Sep. 05, 2023
-
Patent Title: Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator Jun. 27, 2023
-
Patent Title: Glucocorticoid receptor modulators to treat cervical cancer May. 30, 2023
-
Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators May. 16, 2023
-
Patent Title: Glucocorticoid receptor modulators to treat pancreatic cancer May. 09, 2023
-
Patent Title: Systems and methods of managing treatment of a chronic condition by symptom tracking Mar. 21, 2023
-
Patent Title: Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Feb. 28, 2023
-
Patent Title: Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator Feb. 28, 2023
-
Patent Title: Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Feb. 14, 2023
-
Patent Title: Octahydro fused azadecalin glucocorticoid receptor modulators Jan. 24, 2023
-
Patent Title: Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators Jan. 10, 2023
-
Patent Title: Pyrimidine cyclohexenyl glucocorticoid receptor modulators Jan. 03, 2023
-
Patent Title: Treatment of hypercoagulopathy in cushing's syndrome by administration of glucocorticoid receptor modulators Dec. 13, 2022
-
Patent Title: Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound Oct. 11, 2022
-
Patent Title: Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent Jul. 19, 2022
-
Patent Title: Octahydro fused azadecalin glucocorticoid receptor modulators Jun. 28, 2022
-
Patent Title: Treatment and differential diagnosis of cushing's disease and ectopic cushing's syndrome May. 10, 2022
-
Patent Title: Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 Mar. 29, 2022
-
Patent Title: Methods for treating cushing's syndrome Mar. 08, 2022
-
Patent Title: Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent Feb. 01, 2022
-
Patent Title: Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators Jan. 04, 2022
-
Patent Title: Use of acth in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of cushing's syndrome patients Dec. 21, 2021
-
Patent Title: Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency Dec. 21, 2021
-
Patent Title: Optimizing mifepristone levels for cushing's patients Nov. 16, 2021
-
Patent Title: Treatment of muscular dystrophy Aug. 31, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CORT
Recent picks made for CORT stock on CNBC
ETFs with the largest estimated holdings in CORT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CORT stock a Buy, Sell, or Hold?
- What is the price target for $CORT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CORT stock?
- Who owns the most shares of $CORT stock?
- What funds own $CORT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CORT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.